NASDAQ
06.02.26 | 22:00
2,050 US-Dollar
-0,49 % -0,010
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | ALX Oncology Prices $150 Mln Offering Of Shares And Pre-funded Warrants | 3 | RTTNews | ||
| ALX ONCOLOGY Aktie jetzt für 0€ handeln | |||||
| 30.01. | ALX Oncology announces pricing of underwritten offering; shares up nearly 15% | 1 | Seeking Alpha | ||
| 30.01. | ALX Oncology platziert Kapitalerhöhung über 150 Mio. US-Dollar zu 1,57 US-Dollar je Aktie | 2 | Investing.com Deutsch | ||
| 30.01. | ALX Oncology prices $150 million stock offering at $1.57 per share | 3 | Investing.com | ||
| 30.01. | ALX Oncology reports CD47 biomarker findings in breast cancer trial | 2 | Investing.com | ||
| 30.01. | ALX Oncology: CD47-Biomarker könnte Therapieerfolg bei Brustkrebs vorhersagen | 7 | Investing.com Deutsch | ||
| 30.01. | ALX ONCOLOGY HOLDINGS INC - 8-K, Current Report | 2 | SEC Filings | ||
| 30.01. | New Data Demonstrate CD47 Expression Level Helps Predict Response to ALX Oncology's Evorpacept in Combination with Ziihera (zanidatamab-hrii) in Advanced HER2-Positive Breast Cancer | 2 | GlobeNewswire (USA) | ||
| 21.01. | ALX Oncology stockt Aktienprogramm für neue Mitarbeiter auf | 4 | Investing.com Deutsch | ||
| 21.01. | ALX ONCOLOGY HOLDINGS INC - S-8, Securities to be offered to employees in employee benefit plans | 3 | SEC Filings | ||
| 21.01. | ALX ONCOLOGY HOLDINGS INC - 8-K, Current Report | 1 | SEC Filings | ||
| 08.01. | ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004 | 104 | GlobeNewswire (Europe) | - First patient dosed in Phase 2 ASPEN-09-Breast trial evaluating evorpacept in combination with trastuzumab and physician's choice of chemotherapy in HER2-positive metastatic breast cancer; interim... ► Artikel lesen | |
| 08.12.25 | ALXO Presents Phase 2 Data Of Evorpacept In Frontline Indolent Non-Hodgkin Lymphoma At The ASH | 1 | RTTNews | ||
| 07.12.25 | ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting | 189 | GlobeNewswire (Europe) | - Combination of evorpacept plus rituximab and lenalidomide (R2) generated complete responses (CR) in 92% of patients with untreated indolent non-Hodgkin lymphoma (iNHL) comparing favorably to an... ► Artikel lesen | |
| 13.11.25 | Jefferies initiates coverage on ALX Oncology stock with Buy rating | 4 | Investing.com | ||
| 07.11.25 | ALX Oncology anticipates $2B-$4B HER2/CD47 breast cancer market opportunity while advancing biomarker-driven strategies | 6 | Seeking Alpha | ||
| 07.11.25 | ALX ONCOLOGY HOLDINGS INC - 10-Q, Quarterly Report | - | SEC Filings | ||
| 07.11.25 | Earnings Call Transkript: ALX Oncology zeigt vielversprechende Fortschritte bei Medikamentenentwicklung in Q3 2025 | 2 | Investing.com Deutsch | ||
| 07.11.25 | ALX Oncology GAAP EPS of -$0.41 misses by $0.04 | 3 | Seeking Alpha | ||
| 07.11.25 | ALX Oncology Reports Third Quarter 2025 Financial Results and Provides Corporate Update | 219 | GlobeNewswire (Europe) | ASPEN-06 data to be presented at SITC demonstrates that evorpacept drove durable clinical benefit across all efficacy measures in HER2+ gastric cancer patients with high CD47 expression Phase 2 ASPEN-09-Breast... ► Artikel lesen |
1 2 3 Weiter >>
41 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 6,148 | +0,79 % | Zink-Boom, Turnaround, Biotech-Wachstum: So profitieren Sie mit Pasinex Resources, Puma und Evotec | In volatilen Märkten suchen Anleger nach außergewöhnlichen Chancen. Drei Unternehmen stechen dabei heraus. Ein Rohstoffunternehmen mit außergewöhnlichen Zink-Projekten, ein Sportartikelhersteller im... ► Artikel lesen | |
| MODERNA | 34,650 | -0,07 % | Arbutus jumps on ruling in patent dispute with Moderna | ||
| NOVAVAX | 6,910 | -0,80 % | Novavax Licenses Matrix-M Adjuvant To Pfizer For Upfront Payment Of $30 Mln | NEW YORK CITY (dpa-AFX) - Novavax, Inc. (NVAX) announced Tuesday that it has entered into a license agreement with Pfizer, Inc. (PFE) for use of Novavax's Matrix-M adjuvant. Under the terms... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 41,200 | -0,48 % | Morningstar, Inc.: Morningstar Completes Acquisition of CRSP and Extends Relationship with Vanguard | The CRSP integration unites two trusted sources of market insight, reinforcing a shared commitment to transparency, quality, and investor-focused solutions and solidifying Morningstar's position... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,410 | +0,71 % | INOVIO Pharmaceuticals, Inc.: FDA Accepts for Review INOVIO's BLA for INO-3107 for the Treatment of Adults with Recurrent Respiratory Papillomatosis (RRP) | PLYMOUTH MEETING, Pa., Dec. 29, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 10,320 | -0,53 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| DEFENCE THERAPEUTICS | 0,365 | -0,27 % | Defence Therapeutics Inc.: Defence Therapeutics to Present at the World ADC Europe 2026 Showcasing Accum Precision Intracellular Drug-Delivery Platform | Montreal, Quebec--(Newsfile Corp. - February 4, 2026) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a publicly traded biotechnology and precision... ► Artikel lesen | |
| EDITAS MEDICINE | 1,536 | +0,03 % | Editas Medicine, Inc.: Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate | EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 49,320 | +0,28 % | Assessing BioMarin Pharmaceutical: Insights From 5 Financial Analysts | ||
| SAREPTA THERAPEUTICS | 15,680 | +0,16 % | Sarepta gets New Zealand approval for Huntington's disease trial | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,568 | +2,10 % | PacBio Completes Sale of Short-Read Sequencing Assets | MENLO PARK, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the completion of the sale of... ► Artikel lesen | |
| EXELIXIS | 36,900 | -0,67 % | Exelixis stock maintains Buy rating at H.C. Wainwright on FDA review news | ||
| HALOZYME THERAPEUTICS | 68,80 | +0,15 % | Halozyme Therapeutics: Die bessere Evotec? | Halozyme Therapeutics ist den meisten Anlegern hierzulande vermutlich durch den Übernahmeversuch Evotecs vorletztes Jahr bekannt. Eine Akquisition zu 11 € je Aktie scheiterte jedoch, da die Deutschen... ► Artikel lesen | |
| NEUROCRINE BIOSCIENCES | 120,35 | +0,75 % | Neurocrine Biosciences, Inc.: Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1065890 in Adults with Tardive Dyskinesia | SAN DIEGO, Jan. 26, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of its Phase 2 clinical study of investigational... ► Artikel lesen | |
| VAXART | 0,380 | 0,00 % | Vaxart, Inc.: Vaxart Provides Business Update and Reports Third Quarter 2025 Financial Results | Entered into an exclusive license agreement with Dynavax for the Company's COVID-19 oral pill vaccine candidate for potential cumulative proceeds of up to $700 million plus royalties Completed enrollment... ► Artikel lesen |
Das Unternehmen ALX ONCOLOGY HOLDINGS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -0,49 % bei einem Aktienkurs von 2,050 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ALX ONCOLOGY HOLDINGS INC finden Sie auf Wallstreet Online.